Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

231.50
+4.001.76%
Post-market: 231.500.00000.00%16:15 EST
Volume:8.21M
Turnover:1.90B
Market Cap:409.15B
PE:98.09
High:234.74
Open:228.42
Low:228.00
Close:227.50
52wk High:244.81
52wk Low:164.39
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.15
T/O Rate:0.47%
Dividend:6.65
Dividend Rate:2.87%
EPS(TTM):2.36
EPS(LYR):2.36
ROE:1106.67%
ROA:9.59%
PB:-154.86
PE(LYR):98.09

Loading ...

AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch

TIPRANKS
·
4 hours ago

Nxera Pharma Unveils Corporate Presentation Highlighting Global Strategy and Drug Discovery Platform

Reuters
·
Yesterday

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth

TIPRANKS
·
Yesterday

West Pharma forecasts 2026 profit above estimates on strong demand for drug components

Reuters
·
Feb 12

Abbvie Sues U.S. Department of Health and Human Services Over Selection of Botox for Ira Medicare Drug Negotiations

THOMSON REUTERS
·
Feb 12

Abbvie sues US health agency over Botox

Reuters
·
Feb 12

Neurocrine Biosciences Q4 GAAP other income rises 38% to USD 28.5 million

Reuters
·
Feb 12

AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch

TIPRANKS
·
Feb 12

AbbVie’s Real-World Migraine Study Could Quietly Boost Ubrogepant’s Market Potential

TIPRANKS
·
Feb 11

Enanta Pharmaceuticals Q1 revenue beats estimates

Reuters
·
Feb 10

BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating

MT Newswires Live
·
Feb 09

AbbVie Seeks Rinvoq Vitiligo Approval And Extends Immunology Growth Story

Simply Wall St.
·
Feb 08

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 07

AbbVie (ABBV) Receives a Buy from Guggenheim

TIPRANKS
·
Feb 06

CORRECTED-CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)

Reuters
·
Feb 06

Abbvie Inc. : Morgan Stanley Raises Target Price to $270.00 From $269.00

THOMSON REUTERS
·
Feb 05

AbbVie Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Feb 05

AbbVie Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Feb 05

Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating

MT Newswires Live
·
Feb 05